Metraipolis › archive › dc_72e9cd96b164

Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer — Europe PMC PMID:41815543

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41815543
DOI
10.3389/fonc.2026.1728876
License (as archived)
solo-consultazione
Archived
2026-11-05T13:13:47.319Z
SHA-256 of the archived text
e2852292798f95f310adec9a7f1c19811ceccb4bad3f51419a2944bac7470964
Stable URL of this page
https://metraipolis.com/documento/dc_72e9cd96b164

How to cite

Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer — Europe PMC PMID:41815543 — Europe PMC (en), https://europepmc.org/article/MED/41815543 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_72e9cd96b164 (Metraipolis archive dc_72e9cd96b164, sha256 e2852292798f95f310adec9a7f1c19811ceccb4bad3f51419a2944bac7470964)
BibTeX
@misc{dc72e9cd96b164,
  title = {Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer — Europe PMC PMID:41815543},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41815543},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_72e9cd96b164; sha256 e2852292798f95f310adec9a7f1c19811ceccb4bad3f51419a2944bac7470964},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41815543. Agents can read the archived copy with the MCP tool read_document.